A new fluocinolone acetonide intravitreal implant (Yutiq, EyePoint Pharmaceuticals) that is expected to release a fixed-corticosteroid dose for 3 years is now commercially available for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
Reviewed by David Callanan, MD
Following the FDA approval of the fluocinolone acetonide (FA) 0.18 mg intravitreal implant (Yutiq, EyePoint Pharmaceuticals) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye in October 2018, the product was launched for commercial use in February 2019.
According to uveitis specialist, David Callanan, MD, access to the sustained-release corticosteroid implant is a welcome development because it provides clinicians with another great tool for treating appropriately selected patients affected by this sight-threatening disease.
“Every uveitis patient with posterior uveitis is unique, and individuals may respond differently to different medications,” said Dr. Callanan, partner, Texas Retina Associates, and clinical professor of ophthalmology, University of Texas Southwestern Medical School, Dallas.
“Locally administered corticosteroids, however, are generally very effective, and the ability to treat locally is important, especially for avoiding exposure to toxicities of systemic medications in patients who do not have associated extraocular findings or for those whose uveitis is not responding adequately to systemic immunomodulatory therapy.”
“Phase III study results demonstrate that the new FA implant was effective for lowering recurrence rates through the available 6 and 12 months of follow-up, and the safety data on IOP elevation are encouraging so far,” he said. “The trials are ongoing, and we look forward to longer-term findings.”
David Callanan, MD
E: [email protected]
Dr. Callanan is an investigator in one of the phase III FA 0.18 mg implant clinical trials and is a consultant to EyePoint Pharmaceuticals.